S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
Denmark says Nord Stream 1 pipelines stop leaking
Brazil holds historic election with Lula against Bolsonaro
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
US shift away from coal hits tribal community in New Mexico
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
Denmark says Nord Stream 1 pipelines stop leaking
Brazil holds historic election with Lula against Bolsonaro
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
US shift away from coal hits tribal community in New Mexico
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
Denmark says Nord Stream 1 pipelines stop leaking
Brazil holds historic election with Lula against Bolsonaro
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
US shift away from coal hits tribal community in New Mexico
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
Denmark says Nord Stream 1 pipelines stop leaking
Brazil holds historic election with Lula against Bolsonaro
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
US shift away from coal hits tribal community in New Mexico
Allies aim for risky Russian oil price cap as winter nears
NASDAQ:CRSP

CRISPR Therapeutics - CRSP Earnings Date, Estimates & Call Transcripts

$65.35
+0.86 (+1.33%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$64.50
$68.06
50-Day Range
$61.10
$81.40
52-Week Range
$42.51
$112.39
Volume
1.28 million shs
Average Volume
1.11 million shs
Market Capitalization
$5.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$112.33

Earnings Summary

Upcoming
Earnings Date
Nov. 2Estimated
Actual EPS
(Aug. 8)
-$2.40 Missed By -$0.17
Consensus EPS
(Aug. 8)
-$2.23
Last Year's Q3 EPS
(7/29/2021)
$9.44
Skip Charts & View Estimated and Actual Earnings Data

CRSP Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

CRSP Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

CRISPR Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20226($2.13)($1.68)($1.94)
Q2 20227($2.37)($1.92)($2.14)
Q3 20228($2.44)($1.81)($2.22)
Q4 20228($2.51)($1.34)($2.06)
FY 202229($9.45)($6.75)($8.36)
Q1 20234($2.55)($1.86)($2.21)
Q2 20234($2.74)($1.88)($2.34)
Q3 20234($2.92)($1.90)($2.30)
Q4 20234($3.23)($0.07)($1.26)
FY 202316($11.44)($5.71)($8.11)
Q1 20241($2.22)($2.22)($2.22)
Q2 20241($1.97)($1.97)($1.97)

CRSP Earnings Date and Information

CRISPR Therapeutics last released its quarterly earnings results on August 8th, 2022. The reported ($2.40) earnings per share for the quarter, missing analysts' consensus estimates of ($2.23) by $0.17. The firm earned $0.20 million during the quarter, compared to the consensus estimate of $2.20 million. Its revenue for the quarter was down 100.0% on a year-over-year basis. CRISPR Therapeutics has generated ($8.23) earnings per share over the last year (($8.23) diluted earnings per share). Earnings for CRISPR Therapeutics are expected to grow in the coming year, from ($9.26) to ($7.59) per share. CRISPR Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 2nd, 2022 based off prior year's report dates.

CRISPR Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/2/2022
(Estimated)
        
8/8/2022Q2 2022($2.23)($2.40)($0.17)($2.40)$2.20 million$0.20 million
5/9/2022Q1 2022($1.91)($2.32)($0.41)($2.32)$2.45 million$0.94 million
2/14/2022Q4 2021($1.74)($1.84)($0.10)($1.84)$5.39 million$12.90 million    
11/3/20219/30/2021($1.75)($1.67)+$0.08($1.67)$3.85 million$0.82 million
7/29/20216/30/2021$3.52$9.44+$5.92$9.44$678.05 million$900.70 million
4/26/20213/31/2021($1.47)($1.51)($0.04)($1.51)$4.99 million$0.54 million
2/15/202112/31/2020($1.27)($1.50)($0.23)($1.50)$4.69 million$0.37 million
11/2/20209/30/2020($1.18)($1.32)($0.14)($1.32)$2.22 million$0.15 million
7/27/20206/30/2020($0.95)($1.30)($0.35)($1.30)$19.77 million$0.04 million
4/28/20203/31/2020($1.05)($1.15)($0.10)($1.15)$3.04 million$0.16 million
2/12/2020Q4 2019($0.68)$0.51+$1.19$0.51$39.08 million$77.00 million
10/28/2019Q3($0.9480)$2.40+$3.3480$2.40$6.32 million$211.93 million
7/29/2019Q2($0.17)($1.01)($0.84)($1.01)$47.57 million$0.32 million
4/29/2019Q1($0.90)($0.93)($0.03)($0.93)$1.50 million$0.30 million
2/25/2019Q4 2018($0.83)($0.92)($0.09)($0.92)$1.56 million$0.10 million
11/8/2018Q3($0.74)($1.07)($0.33)($1.07)$2.64 million$0.56 million
8/8/2018Q2($0.6310)($0.82)($0.1890)($0.82)$1.47 million$1.09 million
5/9/20183/31/2018($0.67)($0.62)+$0.05($0.62)$3.64 million$1.36 million
11/8/2017Q3($0.60)($0.62)($0.02)($0.62)$3.61 million$2.39 million
8/10/20176/30/2017($0.62)($0.56)+$0.06($0.56)$3.29 million$3.60 million
5/11/20173/31/2017($0.60)($0.54)+$0.06($0.54)$2.70 million
3/10/2017Q4 2016($0.38)($0.40)($0.02)($1.20)$2.34 million
11/22/2016Q3 2016($2.77)($2.77)($2.77)$1.55 million












CRISPR Therapeutics Earnings - Frequently Asked Questions

When is CRISPR Therapeutics's earnings date?

CRISPR Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 2nd, 2022 based off last year's report dates. Learn more on CRSP's earnings history.

Did CRISPR Therapeutics beat their earnings estimates last quarter?

In the previous quarter, CRISPR Therapeutics (NASDAQ:CRSP) missed the analysts' consensus estimate of ($2.23) by $0.17 with a reported earnings per share (EPS) of ($2.40). Learn more on analysts' earnings estimate vs. CRSP's actual earnings.

How much revenue does CRISPR Therapeutics generate each year?

CRISPR Therapeutics (NASDAQ:CRSP) has a recorded annual revenue of $914.96 million.

How much profit does CRISPR Therapeutics generate each year?

CRISPR Therapeutics (NASDAQ:CRSP) has a recorded net income of $377.66 million. CRSP has generated -$8.23 earnings per share over the last four quarters.

What is CRISPR Therapeutics's EPS forecast for next year?

CRISPR Therapeutics's earnings are expected to grow from ($9.26) per share to ($7.59) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:CRSP) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.